ArticlePrzeglad menopauzalny = Menopause review2024
Serum fibronectin levels in malignant and benign endometrial diseases.
Article in Przeglad menopauzalny = Menopause review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic Variations in the Fibronectin 1 Gene (International journal of molecular sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endometrial cancer is currently the most common malignancy of the female reproductive system. The significance of the disease is determined by the search for additional biomarkers with the aim to optimize earlier diagnosis and to help for timely treatment. The objective of this study was to assess the serum levels of fibronectin (FN) in patients with malignant endometrial pathology and to compare them with patients with benign pathology and healthy women. Material and methods: We analyzed serum FN levels in women with malignant and benign pathology of the endometrium. Blood serum samples were collected from 100 patients - 50 diagnosed with endometrial cancer and 50 with confirmed endometrial polyps. In addition, 50 control subjects were tested. Fibronectin levels were measured by enzyme-linked immunosorbent assay (ELISA) according to the protocol. Results: Statistical analysis was performed and the results demonstrated statistical significances ( Conclusions: The serum FN concentration can be used as an additional tumor marker for gynecological malignancies and can be a potential diagnostic and prognostic marker for malignant endometrial pathology as well as for other gynecological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.